The paper considers a clinical example of current therapy for idiopathic pulmonary arterial hypertension in a female patient with its clinical deterioration. It shows the tactics of switching from one drug (bosentan) to others (macitentan) within in the same pathogenetic therapy group (endothelin receptor antagonists). The latest pulmonary hypertension classification (Nice, 2013) is presented. The current strategies of pathogenetic therapy for pulmonary hypertension are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17116/terarkh2017899100-103 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!